10 patients with locally advanced renal cell carcinoma and 5 patients with metastatic renal cell carcinoma were treated with IL-2 subcutaneously. Adverse effects were not important. This study shows that IL-2 alone given subcutaneously is an effective and well-tolerated treatment for renal cell carcinoma.
WestW.H., TauerK.W., YannelliJ.R., MarshallG.D., OrrD.W., ThurmanG.B., OldhamR.K.: Costant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med., 316: 898–905, 1987.
2.
AtzpodienJ., KorferA., FranksC.P., PoliwodaH.M., KirchnerH.: Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet335: 1509–12, 1990.
3.
PalmerP.A., VinkeJ., FhilipT., NegrierS., AtzpodienJ., KirchnerH., OskamR., FranksC.P.: Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.
